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Abstract
Objective To evaluate the use of routine laboratory monitoring in terms
of clinical outcomes among patients receiving antiretroviral therapy (ART)
in Uganda.
Design Randomised clinical trial
Setting A home based ART programme in rural Uganda.
Participants All participants were people with HIV who were members
of the AIDS Support Organisation. Participants had CD4 cell counts
<250 cells × 10
6/L or World Health Organization stage 3 or 4 disease.
Interventions Participants were randomised to one of three different
monitoring arms: a viral load arm (clinical monitoring, quarterly CD4
counts, and viral load measurements), CD4 arm (clinical monitoring and
CD4 counts), or clinical arm (clinical monitoring alone).
Main outcome measures Serious morbidity (newly diagnosed AIDS
defining illness) and mortality.
Results 1094 participants started ART; median CD4 count at baseline
was 129 cells × 10
6/L. Median follow-up was three years. In total, 126
participants died (12%), 148 (14%) experienced new AIDS defining
illnesses, and 61(6%) experienced virological failure, defined as two
consecutive viral loads >500 copies/mL occurring more than three months
after the start of ART. After adjustment for age, sex, baseline CD4 count,
viral load, and body mass index, the rate of new AIDS defining events
or death was higher in the clinical arm than the viral load arm (adjusted
hazard ratio 1.83, P=0.002) or the CD4 arm (1.49, P=0.032). There was
no significant difference between the CD4 arm and the viral load arm
(1.23, P=0.31).
Conclusion In patients receiving ART for HIV infection in Uganda,
routine laboratory monitoring is associated with improved health and
survival compared with clinical monitoring alone.
Trial registration Clinical Trials NCT00119093.
Introduction
Access to antiretroviral therapy (ART) in Africa increased
dramatically over the past decade, beginning with a few
thousandpeopleandreachingfivemillionpeoplebymid-2010.
1
Thisadvancewasbecauseofthereducedcostofdrugs,increased
resources,expandedHIVtesting,andactivism.Otherobstacles
continue to limit the number of people taking ART and the
ability of health systems to effectively monitor patients,
including inadequate number of physicians and allied health
staff
2 and limited laboratory capacity.
3
InmanyAfricancountriestheannualcostofquarterlyCD4cell
counts and measurements of viral load exceeds the cost of
generic first line ART.
4 In addition, establishing sophisticated
laboratoryservicesatrelativelypoorlyequippedhealthfacilities
remains challenging. Consequently, many people taking ART
in Africa receive either no routine laboratory follow-up or
infrequentmeasurementsofCD4cellcounts.
3WhenCD4testing
is used as a routine component of care, most programmes offer
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Research
RESEARCHit only once every six or 12 months.
5 6 A smaller proportion
provide routine viral load testing.
7 8
High viral load and low CD4 cell count are independently
associatedwithmortality,
9-11andchangesinviralloadandCD4
cellcountduringtreatmenthavebeenassociatedwithsurvival.
11
Routine monitoring of viral load and CD4 cell counts during
ART, however, was adopted in well resourced settings without
studies indicating improved survival compared with careful
clinical monitoring. One recent mathematical model showed
little benefit and considerable cost even during 20 years of
follow-up.
12 Furthermore, programmes in Haiti
13 and Malawi
14
havereportedtreatmentsuccesswithclinicalmonitoringalone,
although no groups with laboratory monitoring were available
forcomparison.Byreducingoreliminatingfrequentlaboratory
monitoring,thereispotentialforincreasingthenumberofpeople
whocouldbetreated.Reducedlaboratorymonitoring,however,
might also lead to premature or delayed changes to second line
treatment,moreantiretroviralresistance,orincreasedmorbidity.
Changes in CD4 cell counts do not accurately predict
suppression of viral load.
15-17 A recently reported randomised
clinical trial examining different monitoring strategies for
individualsreceivingARTfoundonlymarginalclinicalbenefits
in terms of mortality associated with providing six monthly
monitoring of CD4 cell count in addition to clinical monitoring
inUgandaandZimbabwe.
18Furthermore,theauthorsconcluded
that the addition of monitoring CD4 cell counts was not cost
effective according to current WHO guidelines.
WHO guidelines provide flexible recommendations for
monitoring people taking ART.
19 We initiated a randomised
clinical trial in Uganda to empirically evaluate whether routine
monitoring of viral loads and CD4 cell count provides clinical
benefits to individuals receiving ART in sub-Saharan Africa.
Methods
Study design
BeginninginMay2003,afterreceivingwritteninformedconsent
we assessed adults aged ≥18 with HIV-1 who were clients of
the Tororo Branch of the AIDS Support Organization (TASO)
for eligibility for study enrolment. Enrolment was offered to
clients with a CD4 cell count <250 cells × 10
6/L or severe HIV
disease (defined as WHO stage 3 or 4 or a history of recurrent
herpes zoster), a serum aspartate aminotransferase (AST) or
alanineaminotransferase(ALT)activitylessthanfivetimesthe
upper limit of normal, a calculated creatinine clearance ≥0.42
mL/s, and a Karnofsky score of >40%; isolated pulmonary
tuberculosis alone was not an inclusion criterion because in
Africa it is common among people with HIV even without
immunocompromise. Participants who had taken ART
previously were enrolled in the study, but unless use consisted
onlyofnevirapineforpreventionofmothertochildtransmission
they were excluded from analyses.
Investigators used a random number generator and blocked
randomisation to assign participants to one of three different
monitoring regimens: the “viral load arm,” with quarterly HIV
viral loads and CD4 cell counts and weekly home visits by a
trainedlaypersonusingastandardisedsymptomquestionnaire;
the “CD4 arm,” with quarterly CD4 cell counts and weekly
home visits; or the “clinical arm,” with weekly visits alone. All
participantshadmeasurementsofviralloadandCD4cellcount
performed on quarterly blood samples. Results of these were
made available to study physicians as appropriate to the
participants’assignmentarm.AllparticipantsunderwentaCD4
cell count at study enrolment to determine eligibility for ART.
Follow-up continued until 4 February 2007.
The first line ART regimen was stavudine, lamivudine, and
nevirapine(orefavirenzforthosetakingconcurrentrifampicin).
Trainedlayfieldofficersvisitedclients’homesweeklytodeliver
drugs and collect data regarding drug adherence, potential
symptoms of drug toxicity, or death of a household member in
the preceding seven days.
20 Prepackaged drugs were replaced
by using a weekly storage container, and pill counts were
conductedatthestudyclinicbyapharmacist.Participantswere
weighed each month during home visits and these weights and
bodymassindex(BMI)scoreswereprovidedtoclinicians.After
enrolment, no routine clinic visits were scheduled but
participants were encouraged to come to the clinic or hospital
iftheywereillandweretransportedtotheclinicforassessment
if they had specifically defined symptoms or severe illness
during a home visit.
Cryptococcal disease was diagnosed by compatible symptoms
and serum cryptococcal antigen testing (Crypto-LA, Wampole
Laboratories, Cranberry, NJ). Pulmonary tuberculosis was
definedaspositiveresultsforacidfastbacilliduringmicroscopy
fromtwosputumsmearsornegativeresultsfromsputumsmears
but with chest radiography compatible with tuberculosis and a
lack of response to a two week trial of antibiotics.
Extrapulmonary tuberculosis was diagnosed by clinical
presentation and occasionally by lymph node biopsy and
pathological confirmation. Diagnoses of Kaposi’s sarcoma and
cervical cancer were based on biopsy results. Pneumocystis
jirovecii pneumonia was diagnosed clinically with chest
radiography, clinical presentation, and a response to
cotrimoxazoletreatment.Monitoringanddiagnosticprocedures
for the occurrence of illness did not differ between study arms.
Physicians responsible for patients in the two study arms that
included routine viral loads or CD4 counts, or both, received
these results on a quarterly basis.
Participants continued with daily cotrimoxazole prophylaxis
regardless of CD4 cell count. Participants who met clinical or
laboratorydefinitionsoffailureofARTweregenerallyswitched
to didanosine, tenofovir, and lopinavir/ritonavir.
In the viral load arm, treatment failure was defined as two
consecutiveviralloadmeasurements>500copies/mLoccurring
more than six months after the start of ART. For the CD4
monitoring arm, persistently declining CD4 cell counts on two
consecutivemeasurementswasconsideredtoindicatetreatment
failure. For the clinical arm, predefined primary indications for
treatment change included determination of a new or recurrent
CDC category C condition after three months of ART,
documented unintentional weight loss of ≥10%, constitutional
symptoms such as fever (>38.5°C) or diarrhoea lasting more
than a month without a correctable cause, or new oral or
recurrentvaginalcandidiasis.Pulmonarytuberculosisitselfwas
not an indication for failure. The first response to a worsening
trend in CD4 or viral load was counselling about adherence to
treatment. Supplemental CD4 and viral load assessments could
be ordered during clinic visits. Study physicians, nurses,
counsellors, and other staff met weekly in a case conference
and discussed all deaths, opportunistic illnesses, and abnormal
laboratory results and approved all regimen changes.
Laboratory procedures
PlasmasampleswerescreenedforHIVinfectionbytwoenzyme
linked immunoassays (EIA) in parallel (Recombigen
HIV-1/HIV-2, Trinity Biotech, Dublin; and Murex HIV1.2.0,
Abbott diagnostics, Chicago, IL). Specimens concordantly
positiveornegativereceivednofurthertesting.Specimenswith
discordant results were retested with the same algorithm and,
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RESEARCHif still discordant, by western blotting (LAV Blot, Biorad,
Richmond, VA). HIV viral loads were measured with Cobas
Amplicor HIV-1 Monitor version 1.5 ultrasensitive assay
(Roche,Branchburg,NJ)forbaselinemeasurements,whichhad
a lower limit of detection of 400 copies/mL. Follow-up viral
load measurements were conducted with the Cobas Taqman
(manual extraction) assay, with a lower limit of detection of 50
copies/mL. CD4 cell counts were done with TriTEST reagents
followinganinhousedualplatformprotocolandMultiSETand
Attractors software with a FACScan or FACSCalibur flow
cytometer (Becton-Dickinson, Franklin Lakes, NJ). Complete
blood counts were provided with CD4 cell counts.
Data analysis
The main outcome was a composite of severe AIDS associated
morbidity and mortality (referred to as severe morbidity and
mortality). This included death from any cause, all US Centers
for Disease Control category C illnesses except pulmonary
tuberculosis,andfouradditionalcategoryBillnesses:morethan
one episode of herpes zoster or in multiple dermatomes,
recurrent severe bacterial infections, peripheral neuropathy not
associated with drug toxicity, or oral hairy leucoplakia. We
planned to enrol a minimum of 333 participants in each
monitoring arm. With 80% power and a two sided test at a
median follow-up of three years, this sample size should allow
ustodetectanabsolutedifferenceof8%betweentheproportion
of participants with a serious morbidity or who died in the
clinical arm and the viral load arm if the proportion in the viral
load arm was 12%. Data were entered with Epi Info (CDC,
Atlanta, GA) and analysed with SAS 9.0 (SAS Institute, Cary,
NC).
Fortheprimaryanalysis,weusedanintentiontotreatapproach
including all randomised participants. We also performed per
protocol analyses that included only participants who received
ART for at least 90 days as the different monitoring regimens
would not theoretically affect outcomes until the time of the
firstbloodsample.WedevelopedKaplan-Meiersurvivalcurves
to compare outcomes and used multivariable Cox regression
models to adjust for possible associations with morbidity and
mortality, with a backward stepwise approach. Hazard ratios
andincidencerateratioswereadjustedforage,sex,andbaseline
CD4cellcount,viralload,andBMI,unlessotherwisespecified.
A P value <0.05 was considered significant. We assessed the
proportionality assumption of time dependent covariates—that
is,interactionbetweenmonitoringarmsandtime,andover-and
under- dispersion of data. For analyses of the incidence of
illnesses, we used a Poisson regression model with a log link
function.Persontimeforpeoplelosttofollow-uportransferred
toadifferentproviderwascensoredatthetimeofthelasthome
visit at which they received ART. We estimated adherence by
calculating a weekly drug possession ratio that incorporated an
individual’spillcountdataandanylapsesindeliverythatcould
have occurred because of drug holidays or being away from
home.
A data safety monitoring board reviewed data every three
monthsandwasaskedtorejectthenullhypothesisofmonitoring
arm equivalence if the rate of severe morbidity and mortality
in any arm exceeded another by three standard errors of the
difference (“Haybittle-Peto” rule).
21
Results
Of 1956 adults evaluated for enrolment, 1160 (59%) were
eligible for ART and randomised to one of the three arms. Of
these, 44 (4%) were excluded from analysis because they had
previouslyreceivedART,leaving368intheviralloadarm,371
intheCD4arm,and377intheclinicalarm(fig1⇓).Themedian
age was 38 (interquartile range 32-44); 73% were women; and
the median baseline CD4 cell count was 129 cells × 10
6/L
(64-195). Demographic and clinical parameters were similar
across study arms, except that fewer women were enrolled in
the clinical arm (table 1⇓).
After inclusion in the study, 360 participants in the viral load
arm, 364 in the CD4 arm, and 370 in the clinical arm started
ART. Median follow-up was three years (interquartile range
2.9-3.2) and was similar across arms. The median time from
the first CD4 cell count to initiation of ART was 28 days
(22-37). Table 2⇓ shows the time to first event analysis, with
anintentiontotreatapproachfromthetimeofinitiationofART.
Forty seven individuals experienced at least one serious
morbidity or died in the viral load arm, 58 in the CD4 arm, and
72 in the clinical arm (table 2⇓). In a Cox proportional hazards
model with adjustment for baseline age, sex, CD4 cell count,
viral load, and BMI, participants in the clinical arm were more
likely to have at least one episode of serious morbidity or die
compared with participants in the viral load arm (7.6 v 4.8 per
100 person years; adjusted hazard ratio 1.83, 95% confidence
interval1.25to2.69)andtheCD4arm(7.6v6.0per100person
years; 1.49, 1.03 to 2.13). There was no significant difference
in the risk of first serious morbidity or death between the CD4
arm and the viral load arm (1.23, 0.82 to 1.84); we had 80%
power to detect a hazard ratio as small as 1.75 at P<0.05.
Figures 2 and 3 show different analyses of time to first event
of severe morbidity or mortality.⇓⇓ The per protocol analysis
comparing events after the first 90 days after initiation of ART
included similar proportions of participants per arm (349/368
(95%) for the viral load arm, 346/371 (93%) for the CD4 arm,
and 352/377 (93%) for the clinical arm; P=0.61) (fig 3) and
found comparable results with the intention to treat analysis
(table 2 and fig 2[f]).
With an intention to treat approach, several CDC category C
illnesses were more common among people in the clinical arm
than in the viral load arm: extrapulmonary tuberculosis (1.4 v
0.3 events per 100 person years; incidence rate ratio 7.27, 1.64
to 32.30); cryptococcal disease (2.2 v 1.1; 2.21, 1.06 to 4.59);
and P jiroveci pneumonia (1.1 v 0.2; 9.57, 1.96 to 46.71) (table
3⇓). Similar results were seen when we compared the clinical
armwiththeCD4arm(table3)andusingaperprotocolanalysis
(datanotshown).Therewerenosignificantdifferencesbetween
the CD4 and viral load arms.
Mortality
With an intention to treat approach from the time of ART
randomisation,126(11%)participantsdied:37intheviralload
arm, 40 in the CD4 arm, and 49 in the clinical arm (table 2⇓);
60/126 (48%) deaths occurred in the first three months.
Participants in the clinical arm were more likely to die than
those in the viral load arm (4.9 v 3.7 per 100 person years;
adjusted hazard ratio 1.57, 1.00 to 2.46) and those in the CD4
arm (4.9 v 4.0 per 100 person years; 1.43, 0.92 to 2.21). There
wasnosignificantdifferenceinmortalitybetweentheCD4and
viralloadarms(1.10.0.69to1.75).Intheperprotocolanalysis,
there were similar but non-significant trends (table 2⇓).
Viral load and CD4 cell count response
At baseline, the median viral load was 216 000 copies/mL
(interquartile range 72 000-536 000). During follow-up, 61
(5.5%)participantshadviralloadmeasurements>500copies/mL
on two consecutive occasions; 16 (4.6%) in the viral load arm,
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RESEARCH26 (7.5%) in the CD4 arm, and 19 (5.4%) in the clinical arm
(P=0.56). Of 1047 participants in the per protocol analysis, 28
(2.8%) were changed to a regimen containing a protease
inhibitor (table 4⇓). Of the 61 participants with virological
failure, 13 were switched to second line regimens: seven (44%)
of 16 in the viral load arm, four (15%) of 26 participants in the
CD4 arm, and two (11%) of 19 in the clinical arm. All
participants who were changed to second line treatment in the
viralloadandCD4armshadatleasttwoconsecutiveviralloads
>500 copies/mL; only two (12%) of 17 patients in the clinical
armwhowereswitchedtosecondlinehadtwoconsecutiveviral
loads >500 copies/mL. Of these 17 patients, all were switched
more than a year after they started ART because of AIDS
definingevents:sixhadcryptococcaldisease,fivehadKaposi’s
sarcoma; one had extrapulmonary tuberculosis, two had >10%
unintentional weight loss, one had cervical cancer; one had
cytomegalovirus infection, and one had recurrent pneumonia.
Eight (47%) participants changed in the clinical arm had CD4
cell counts <200 cells × 10
6/L at the time of their illness.
Among participants with virological failure who were not
switchedtosecondlinetherapythemedianviralloadsixmonths
later was greater for those in the clinical arm (7340 copies/mL,
interquartilerange2315-10350)comparedwith<50copies/mL
(<50-<50) (P=0.002) in the viral load arm and 1340 copies/mL
(<50-9540) (P=0.012) in the CD4 arm. Among the 17 people
in the clinical arm with virological failure who were not
switchedtosecondlinetreament,however,onlytwodeathsand
no opportunistic infections occurred. For participants in the
clinical arm, the mean medication possession ratio was worse
in the three months after viral load failure compared with the
three months before (94.1% v 98.5% of pills taken; mean
pairwise difference 4.5%, 0.4% to 8.5%; P=0.032) but it was
not significantly different for the CD4 arm (99.1% v 98.6%;
−0.5%, −2.3% to 1.3%; P=0.57) or the viral load arm (92.1%
v 100%; 7.9%, −4.2% to 20.1%; P=0.17).
Discussion
The addition of quarterly monitoring of CD4 cell count among
adultstakingARTinUgandawasassociatedwithbetterclinical
outcomes than clinical monitoring alone. Similar results were
seen for the combined end point of new AIDS defining illness
or mortality as well as specific opportunistic illnesses, such as
Cryptococcus infection and tuberculosis.
These results provide reassurance to clinicians and patients in
resource limited settings who have access to CD4 cell counts
but not viral load testing. Most people taking ART in Africa,
however, receive limited laboratory monitoring.
3 22 Although
the benefits associated with laboratory testing were relatively
small compared with the effectiveness of ART in reducing
mortality,
18 23 they were present, and support the continued
expansion of monitoring CD4 cell counts as well as ART.
Several studies have concluded that clinical indicators and
changesinCD4cellcountarenotgoodpredictorsofvirological
failure.
17 24-26Inourstudy,however,peopleintheCD4cellcount
monitoring arm did better than those with clinical monitoring
alone. This could be because CD4 cell counts identified issues
relatedtopooradherencebeforemajorclinicaleventsoccurred.
Most people in the clinical monitoring arm with virological
failure had detectable virus and worsening adherence three to
six months later. In addition, CD4 cell count predicts risk for
clinical events, even with undetectable virus.
27-29
Following current practice, we did not switch regimens in the
viral load monitoring arm if people had a poor immunological
response or new AIDS defining event if they also had
undetectable virus. In the CD4 arm, we changed people if they
had a poor immunological response. All of those individuals
switched, however, had detectable viral load, indicating a
reasonableconcordancebetweenCD4andviralloadmonitoring.
In the clinical arm, however, 88% of people switched to second
line treatment because of the diagnosis of an AIDS defining
illnesshadundetectableviralload.Becausesecondlineregimens
are expensive and there are limited options for third line
treatment in most resource limited settings, use of clinical
monitoring could have additional long term drawbacks.
Routine monitoring of viral load should reduce the amount of
timethatpatientstakeafailingregimenandthereforepotentially
reduce clinical events, decrease the frequency of antiretroviral
drugmutations,andimproveefficacyofsecondlineregimens.
17
We did not find that quarterly viral loads provided additional
clinical benefit to patients. This could have been because of
limited statistical power in our study. The rates of virological
failureinourstudy(6%amongsurvivorswithamedianofthree
years of follow-up) are generally lower than most reported
programmesfromtheregion,assurveyedinarecentsystematic
review.
30Thatreviewincludedfivereportswithfollow-uptimes
of 36 months or more and the proportion of participants with
virological success varied from 58% to 98%. Our study had
excellentadherence,probablybecauseofthehomebaseddesign
and frequent drug delivery, and a more typical setting might
haveseenmoredrugfailureandahigherincidenceofmorbidity
and mortality. Designing programmes that maximise retention
of patients and support adherence to treatment
22 31-33 might be
moreimportantthantheuseoflaboratorymonitoring,andmany
programmes in Africa have had default rates of 20% or more,
34
suggesting potential for improvement.
It is also possible that CD4 cell counts identified people with
virologically defined treatment failure or because monitoring
CD4 cell counts detected correctable problems with adherence
to ART. In addition, all participants switched to second line
treatment in the CD4 cell count monitoring arm had detectable
viral load, and those in the CD4 arm with virological failure
who were not switched mostly had low or undetectable viral
load six months later. Partial
35 or intermittent
36 virological
suppression has been associated with better outcomes than no
change, and even dual ART has positive immunological,
virological, and survival effects.
37
It is not clear whether longer term follow-up would show
benefits to viral load testing. An evaluation with data from
resource limited countries found no evidence of improved
mortalityinprogrammeswithviralloadtesting,
38butfollow-up
was relatively short. In addition, modelling of different data
showed little long term benefit of either viral load or CD4 cell
count monitoring.
12 Resistance to lamivudine and nevirapine is
already present in 90% of patients by the time of virological
failure,
39 40 but the rate of development of thymidine analogue
mutations is variable.
22 41 42 We switched only a few people to
second line regimens and therefore could not assess whether
people who had a longer time with detectable virus before
switching would do less well on second line regimens.
Comparison with other studies
OurresultsarelargelyconsistentwiththoseoftheDevelopment
of Antiretroviral Therapy for Africa (DART) trial, which was
recently completed in two sites in Uganda and one in
Zimbabwe,
18 although we differ somewhat in our interpretation
of these results. Participants in DART were randomised to
clinicalmonitoringaloneorclinicalmonitoringplussixmonthly
monitoring of CD4 cell count. After five years of follow-up,
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RESEARCHsurvivalwas87%(95%confidenceinterval85%to88%)inthe
clinical monitoring arm and 90% (88% to 91%) in the clinical
plus CD4 cell count monitoring arm. Neither group received
routineviralloadtesting.Whiletheauthorsconcludedthatthese
differences were quite small and probably did not justify the
added expense of CD4 cell count testing, they were unable to
showthatclinicalmonitoringwasnotinferiortoCD4cellcount
monitoring. Our associated formal cost effectiveness analysis
of our study further informs the debate regarding appropriate
resource allocation for ART programmes in this region.
43
Strengths and weaknesses
Inthisrandomisedtrialweexaminedtheefficacyofbothroutine
CD4 cell count and viral load monitoring on clinical outcomes
in a resource limited setting. The study does have some
limitations.Althoughparticipantswererandomisedatbaseline,
there were more men in the clinical arm, and at least one study
has found that men have worse clinical outcomes during ART
than women, although this was mostly because of more
advancedimmunodeficiencyandworseadherencetotreatment.
44
To account for this potential issue, we adjusted for sex in all
models.Thevirologicalcriteriaforswitchingwereconservative
in relation to switching criteria in industrialised countries,
45
although more liberal than current WHO recommendations,
19
and could have led to underestimation of the effectiveness of
viral load monitoring in improving clinical outcomes. Also,
because we had few participants with virological failure, we
had limited statistical power to examine the effectiveness of
viral load testing. Lastly, although diagnostic procedures for
opportunistic infections were identical across arms, clinicians
could not be blinded, and they might have more intensively
examined participants in the clinical arm for illness. Some of
the illnesses had clear laboratory or pathological diagnoses,
such as cryptococcal disease and Kaposi’s sarcoma, and there
was increased mortality in the clinical arm that would not be
susceptible to ascertainment bias.
Conclusions and policy implications
The number of people estimated to be acquiring new HIV
infections in the world each year exceeds the number currently
taking ART.
46 As we expand programmes to meet the current
and future need for ART, efforts should be made to increase
access to CD4 cell counts not only for determining eligibility
forARTbutalsoformonitoringpeoplealreadyreceivingART.
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RESEARCHTables
Table 1| Baseline characteristics of participants in study monitoring efficacy of ART, Tororo and Busia Districts, Uganda, 2003-7, according
to type of monitoring: viral load arm (clinical monitoring, CD4 cell count, viral load monitoring), CD4 arm (clinical monitoring, CD4 cell
count), and clinical arm (clinical monitoring only). Figures are numbers (percentage) of patients unless stated otherwise
P value* Clinical arm (n=377) CD4 arm (n=371) Viral load arm (n=368)
0.96 39 (32-44) 38 (32-44) 37 (32-43.5) Median (IQR) age (years)
0.01 67 75 75 Female (%)
CD4 cell count in cells × 10
6/L (IQR):
0.65 131 (70-197) 127 (62-130) 128 (61-194) Median
— 67 (18) 76 (20) 78 (21) <50
— 223 (59) 219 (59) 209 (57) 50-200
— 87 (23) 76 (20) 80 (22) >200
HIV viral load (copies/mL):
0.63 210 000 (74 600-570 000) 201 000 (63 600-520 000) 233 000 (77 900-513 000) Median (IQR)
— 4 (1) 3 (1) 1 (0) <1000
— 15 (4) 11 (3) 16 (4) 1000-9999
— 95 (25) 115 (31) 97 (26) 10 000-99 999
— 263 (70) 242 (65) 253 (69) ≥100 000
0.84 5.2 5.2 5.2 Mean log10copies/mL
Body mass index:
0.98 19.6 (18.0-21.5) 19.7 (18.1-21.5) 19.7 (18-21.5) Median (IQR)
114 (30) 113 (30) 111 (30) <18.5
238 (63) 228 (61) 218 (59) 18.5-24.9
12 (3) 14 (4) 20 (5) 25-29.9
3 (1) 4 (1) 3 (1) ≥30
10 (3) 12 (3) 16 (4) Missing
0.96 112 112 112 Median haemoglobin (g/L)
0.55 32 (8) 33 (9) 31 (8) Aspartate aminotransferase (AST) >1.5 times normal (%)
0.28 16 (4) 9 (2) 9 (2) Alanine aminotransferase (ALT) >1.5 times normal (%)
0.38 10 (3) 11 (3) 6 (2) Creatinine >132.6 µmol/L) (%)
Highest level of education completed:
0.48 182 (48) 205 (55) 198 (54) None
82 (22) 70 (19) 80 (22) Primary
98 (26) 83 (22) 80 (22) More than primary
15 (4) 13 (4) 10 (3) Missing
Marital status:
0.46 17 (5) 16 (4) 15 (4) Single
149 (40) 127 (34) 142 (39) Married/cohabiting
42 (11) 49 (13) 31 (8) Separated/divorced
154 (41) 166 (45) 170 (46) Widowed
15 (4) 13 (4) 10 (3) Missing
0.77 4 (2) 3 (1) 5 (2) Received ART for PMTCT in past (women only)
0.61 352 (93) 346 (93) 349 (95) In per protocol analysis
IQR=interquartile range; PMTCT=preventing mother to child transmission.
*Kruskal-Wallis test for continuous variables or χ
2 or Fisher’s exact test for categorical variables.
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RESEARCHTable 2| Cox proportional hazard models comparing time to first serious morbidity or death, in study monitoring efficacy of ART, Tororo
and Busia Districts, Uganda, 2003-7
Hazard ratio (95% CI); P value
Rate per
100
Person-years
of follow-up Events/participants
Adjusted* Unadjusted
person
years
Compared with
CD4 arm
Compared with viral
load arm
Compared with
CD4 arm
Compared with viral
load arm
Severe morbidity and mortality
Intention to treat†:
— — — — 4.8 979.4 47/368 Viral load arm
— 1.23 (0.82 to 1.84);
0.309
— 1.24 (0.85 to 1.83);
0.269
6.0 971.6 58/371 CD4 arm
1.49 (1.03 to
2.13); 0.032
1.83 (1.25 to 2.69);
0.002
1.24 (0.88 to
1.75); 0.227
1.54 (1.06 to 2.22);
0.022
7.6 950.9 72/377 Clinical arm
Per protocol analysis‡:
— — — — 2.7 884.4 24/349 Viral load arm
— 1.32 (0.76 to 2.31);
0.323
— 1.22 (0.71 to 2.10);
0.466
3.3 877.8 29/346 CD4 arm
1.74 (1.09 to
2.79); 0.021
2.31 (1.38 to 3.84);
0.001
1.64 (1.03 to
2.61); 0.035
2.01 (1.23 to 3.29);
0.005
5.5 852.3 47/352 Clinical arm
All cause mortality
Intention to treat†:
— — — — 3.7 1002.6 37/368 Viral load arm
— 1.10 (0.69 to 1.75);
0.698
— 1.08 (0.69 to 1.69);
0.738
4.0 1008.7 40/371 CD4 arm
1.43 (0.92 to
2.21); 0.109
1.57 (1.00 to 2.46);
0.049
1.21 (0.80 to
1.84); 0.366
1.31 (0.85 to 2.01);
0.217
4.9 1003.4 49/377 Clinical arm
Per protocol analysis‡:
— — — — 2.2 891.9 20/349 Viral load arm
— 1.00 (0.52 to 1.92);
0.99
— 0.90 (0.48 to 1.70);
0.744
2.0 897.8 18/346 CD4 arm
1.63 (0.89 to
2.99); 0.110
1.63 (0.90 to 2.98);
0.109
1.55 (0.86 to
2.80); 0.146
1.40 (0.79 to 2.48);
0.255
3.1 890.1 28/352 Clinical arm
*Adjusted for age, sex, baseline CD4 cell count, baseline viral load, and baseline BMI.
†Includes all randomised participants, irrespective of whether they had started ART.
‡Includes only those participants who survived beyond first 90 days of receipt of ART and includes only events that occurred after this point.
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RESEARCHTable 3| Poisson regression models comparing number of events, in study monitoring efficacy of ART, Tororo and Busia Districts, Uganda,
2003-2007. Intention to treat analysis unless otherwise specified
Incidence ratio (95% CI); P value
Rate per
100
Person-years
of follow-up Episodes/participants
Adjusted* Unadjusted
person
years
Compared with
CD4 arm
Compared with viral
load arm
Compared with
CD4 arm
Compared with viral
load arm
New CDC category C illnesses
— — — — 3.3 1002.6 33/368 Viral load arm
— 1.62 (0.83 to 3.15);
0.158
— 1.39 (0.89 to 2.17);
0.153
4.6 1008.7 46/371 CD4 arm
2.08 (1.25 to
3.46); 0.005
3.37 (1.84 to 6.14);
<0.0001
1.46 (1.01 to
2.13); 0.046
2.03 (1.34 to 3.08);
0.001
6.7 1003.4 67/377 Clinical arm
New CDC category C illnesses (per protocol analysis)
— — — — 1.7 891.9 15/349 Viral load arm
— 1.34 (0.84 to 2.15);
0.222
— 1.52 (0.79 to 2.92);
0.205
2.6 897.8 23/346 CD4 arm
1.84 (1.24 to
2.73); 0.002
2.47 (1.60 to 3.82);
<0.0001
2.02 (1.22 to
3.33); 0.006
3.07 (1.72 to 5.50);
0.0002
5.2 890.1 46/352 Clinical arm
Tuberculosis
— — — — 2.9 1002.6 29/368 Viral load arm
— 0.92 (0.53 to 1.61);
0.783
— 0.93 (0.55 to 1.56);
0.772
2.7 1008.7 27/371 CD4 arm
1.69 (1.01 to
2.85); 0.047
1.56 (0.94 to 2.60);
0.084
1.38 (0.84 to
2.26); 0.206
1.27 (0.78 to 2.07);
0.328
3.7 1003.4 37/377 Clinical arm
Extrapulmonary tuberculosis
— — — — 0.3 1002.6 3/368 Viral load arm
— 3.02 (0.61 to 15.01);
0.177
— 2.32 (0.60 to 8.97);
0.223
0.7 1008.7 7/371 CD4 arm
2.41 (0.92 to
6.33); 0.074
7.27 (1.64 to 32.30);
0.009
2.01 (0.81 to
4.98); 0.131
4.66 (1.34 to 16.23);
0.016
1.4 1003.4 14/377 Clinical arm
Cryptococcal infection
— — — — 1.1 1002.6 11/368 Viral load arm
— 0.74 (0.30 to 1.84);
0.516
— 0.99 (0.43 to 2.29);
0.989
1.1 1008.7 11/371 CD4 arm
2.99 (1.32 to
6.77); 0.009
2.21 (1.06 to 4.59);
0.034
2.01 (0.97 to
4.15); 0.059
2.00 (0.97 to 4.12);
0.061
2.2 1003.4 22/377 Clinical arm
Kaposi’s sarcoma
— — — — 0.4 1002.6 4/368 Viral load arm
— 1.50 (0.42 to 5.35);
0.528
— 1.74 (0.51 to 5.94);
0.377
0.7 1008.7 7/371 CD4 arm
1.83 (0.67 to
5.01); 0.239
2.75 (0.87 to 8.70);
0.084
1.58 (0.61 to
4.08); 0.344
2.75 (0.87 to 8.63);
0.083
1.1 1003.4 11/377 Clinical arm
Pneumocystis jirovecii pneumonia
— — — — 0.2 1002.6 2/368 Viral load arm
— 0.58 (0.05 to 6.46);
0.659
— 0.50 (0.05 to 5.48);
0.568
0.1 1008.7 1/371 CD4 arm
16.5 (2.04 to
132.6); 0.009
9.57 (1.96 to 46.71);
0.005
11.06 (1.43 to
85.7); 0.021
5.50 (1.22 to 24.79);
0.027
1.1 1003.4 11/377 Clinical arm
*Adjusted for age, sex, baseline CD4 cell count, baseline viral load, and BMI.
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RESEARCHTable 4| Viral load response and switch to second line regimens in study monitoring efficacy of ART, Tororo and Busia Districts, Uganda,
2003-7. Figures are numbers (percentages where shown)
Changed to second line with
detectable viral load Total changed to second line
Proportion changed to second
line
≥2 viral loads >500 copies/mL after 90
days
7/7 (100) 7 7/16 (44) 16/349 (4.6) Viral load
4/4 (100) 4 4/26 (15) 26/346 (7.5) CD4
2/17 (12) 17 2/19 (11) 19/352 (5.4) Clinical
13/28 (46) 28/1047 (2.8) 13/61 (21) 61/1047 (5.5) All
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RESEARCHFigures
Fig 1 Trial profile of participants with HIV enrolled and followed up in study monitoring efficacy of ART, Tororo and Busia
Districts, Uganda, 2003-7
Fig 2 Time to first event of severe morbidity or mortality, intention to treat analysis, Tororo and Busia Districts, Uganda,
2003-7 (log rank P=0.067). P=0.02 for viral load v clinical, P=0.22 for CD4 v clinical, P=0.26 for viral load v CD4
Fig 3 Time to first severe morbidity event or death, per protocol analysis excluding first 90 days of ART, Tororo and Busia
Districts, Uganda, 2003-7 (log rank P<0.009). P=0.004 for viral load v clinical, P=0.034 for CD4 v clinical, P=0.46 for viral
load v CD4
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